Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-UK bribery investigation adds to Glencore's legal headaches

Thu, 05th Dec 2019 13:45

* Scope of SFO investigation is unclear

* DoJ is already investigating Glencore

* Share price down 9% to 3-year low

* Law firm plans legal action on behalf of investors
(Adds comments from sources, share price, lawsuit, dateline)

By Yadarisa Shabong, Julia Payne and Kirstin Ridley

LONDON, Dec 5 (Reuters) - The UK's Serious Fraud Office
(SFO) has launched a bribery investigation into Glencore
, adding to legal troubles that have hit the shares of
one of the world's biggest miners and commodity traders.

The SFO said on Thursday it had opened an investigaton into
suspicions of bribery in the conduct of business by the Glencore
group of companies, its officials, employees, agents and
associated persons in June. It declined to comment on the scope
of its inquiry.

The London-listed shares of Glencore, which has operations
in over 150 countries, fell 9% to 216.9 pence, their lowest
level in more than three years, knocking 2.6 billion pounds
($3.3 billion) off the company's market value.

Glencore, which was subpoenaed in July 2018 by the U.S.
Department of Justice over possible violations of the Foreign
Corrupt Practices Act relating to operations in Nigeria,
Venezuela and the Democratic Republic of Congo (DRC), said it
would cooperate with the investigation.

Two sources familiar with the matter said the SFO had
recently sought information relating to Glencore's involvement
in the DRC and its former business partner, Israeli billionaire
businessman Dan Gertler.

Reuters was unable to ascertain whether those enquiries were
part of the SFO's bribery probe.

A London-based spokesman for Gertler declined to comment.

Gertler was sanctioned by the United States in 2017 over
allegations he used his friendship with former DRC President
Joseph Kabila to secure sweetheart mining deals. He denied all
allegations of impropriety at the time.

Over the course of this year, Glencore's shares have fallen
more than 20%, pressured by broader concerns about safety and
sustainability in the DRC. Canada's regulatory authorities fined
a Glencore-controlled subsidiary last year after allegations of
inadequate financial disclosures in the DRC.

The legal difficulties have upset shareholders. Boies
Schiller Flexner, a London-based law firm, said it was mounting
a fully-funded legal action on behalf of institutional investors
against Glencore for damages that could exceed 1.0 billion
pounds.

Glencore's CEO Ivan Glasenberg told investors earlier this
week he expected to step down next year once a new management
team is in place.

The investigation is one of the most high-profile SFO probes
launched under Lisa Osofsky, a former FBI lawyer appointed
director last August, who has come under fire for abandoning
some of the agency's most prominent and lengthy probes.

The SFO dropped its investigations into aero engine maker
Rolls-Royce and drugs maker GlaxoSmithKline in
February and ended a seven-year, Libor benchmark interest rate
inquiry in February.

($1 = 0.7794 pounds)

(Additional reporting by Yadarisa Shabong in Bengaluru;
Alistair Smout, Barbara Lewis and Zandi Shabalala in London;
Editing by Jane Merriman and Elaine Hardcastle)

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.